| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -16,699,837 | -142,340,600 | -29,657,362 | -24,369,193 |
| Depreciation of property and equipment | 1,266,513 | 1,180,710 | 1,249,968 | 2,432,577 |
| Amortization of intangible assets | 21,038 | 1,382,612 | 1,448,548 | 2,751,441 |
| Amortization of finance lease right-of-use assets | 1,359,556 | 1,384,912 | 1,272,716 | 2,558,381 |
| Loss (gain) on disposal of fixed assets | -62,493 | 4,000 | -10,453 | -33,215 |
| Deferred income tax expense | -253,775 | 30,061,721 | -13,510,442 | -8,806,213 |
| Accretion of discount related to restricted investments | 78,004 | 94,953 | 69,486 | 145,403 |
| Loss on equity method investments | 0 | -446,213 | -27,035 | -79,515 |
| Bad debt expense | 1,732,911 | 8,341,116 | 1,214,666 | 2,492,009 |
| Stock-based compensation | 3,224,784 | 3,135,898 | 4,649,675 | 9,656,445 |
| Loss on remeasurement of operating and finance leases | 0 | 0 | 5,077 | -47,444 |
| Loss on liquidation of business | NaN | 0 | NaN | NaN |
| Intangible asset impairment | NaN | 30,648,245 | NaN | NaN |
| Finite-lived intangible asset impairment | NaN | NaN | 8,020,343 | NaN |
| Goodwill impairment | NaN | 49,509,698 | 8,718,398 | NaN |
| Equity investment impairment | NaN | 5,000,000 | NaN | NaN |
| Loss on change in fair value of contingent consideration | 2,760,000 | 1,003,718 | 1,052,394 | 0 |
| Accounts receivable | 2,803,766 | -11,775,279 | -14,528,162 | -86,194,306 |
| Prepaid expenses and other current assets | 37,672 | -2,003,275 | 129,747 | 5,273,060 |
| Other assets | -16,374 | 616,919 | -55,463 | -970,612 |
| Accounts payable | 2,700,501 | 2,680,565 | -2,074,591 | -18,246,793 |
| Accrued liabilities | 1,938,714 | -7,730,838 | 4,780,386 | -7,451,661 |
| Operating lease liabilities and right-of-use assets | 132,363 | -213,609 | 77,234 | 336,596 |
| Net cash (used in) provided by operating activities | -4,657,807 | -10,467,300 | 1,658,736 | 43,260,218 |
| Purchase of property and equipment | 430,310 | 1,497,058 | 876,177 | 2,170,883 |
| Purchase of intangibles | 665,172 | 631,147 | 681,396 | 1,578,173 |
| Purchase of equity method investments | NaN | 0 | 4,784 | 0 |
| Acquisition of a business, net of cash acquired | 0 | 12,748,660 | 0 | 3,646,318 |
| Purchase of equity securities | NaN | 0 | NaN | NaN |
| Purchase of restricted investments | 1,731,066 | 3,874,540 | 2,517,699 | 22,221,437 |
| Proceeds from sale and maturity of restricted investments | 4,463,765 | 5,675,359 | 5,158,673 | 2,329,246 |
| Proceeds from disposal of property and equipment | 21,903 | 4,000 | 20,838 | 177,329 |
| Proceeds from exercise of stock options | NaN | 0 | 0 | 0 |
| Net cash provided by (used in) investing activities | 1,659,120 | -13,072,046 | 1,099,455 | -27,110,236 |
| Proceeds from revolving credit line | NaN | 0 | 0 | 0 |
| Repayments of revolving credit line | NaN | 0 | 30,000,000 | 0 |
| Proceeds from notes payable | NaN | 0 | 258,700 | NaN |
| Repayments of notes payable | 14,551 | 14,086 | 20,903 | 6,258 |
| Due to seller | NaN | 19,851 | 106,943 | 750,919 |
| Acquisition of noncontrolling interest | NaN | 0 | 0 | NaN |
| Earnout payments on contingent liabilities | 0 | 0 | 1,687,134 | 265,538 |
| Distributions paid to noncontrolling interest | 1,024,270 | 0 | 175,831 | 0 |
| Payments for taxes related to shares withheld for employee taxes | 22,203 | 410,810 | 62,547 | 1,340,552 |
| Common stock repurchased | 0 | 0 | 0 | 10,828,906 |
| Payments on obligations under finance lease | 1,403,655 | 1,419,963 | 1,256,945 | 2,708,673 |
| Net cash used in financing activities | -2,464,679 | -1,864,710 | -33,051,603 | -15,900,846 |
| Effect of exchange rate changes on cash and cash equivalents | -206,076 | 281,662 | -653,988 | 968,129 |
| Net decrease in cash, cash equivalents, restricted cash and restricted cash equivalents | -5,669,442 | -25,122,394 | -30,947,400 | 1,217,265 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period | 52,484,778 | 77,607,172 | 107,337,307 | NaN |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period | 46,815,336 | 52,484,778 | 77,607,172 | NaN |
DocGo Inc. (DCGO)
DocGo Inc. (DCGO)